Chronic Idiopathic Constipation 2017 approves by FDA
U.S. The Food and Drug Administration has approved the trulance (Pulcnactide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
“Any medicine works for all patients suffering from chronic gastrointestinal disorders,” said Julie Beitz, MD, Director of the Office of Pharmaceutical Evaluation III at the FDA Drug Assessment and Research Center. “With the availability of new therapy, patients and their doctors can choose the best treatment for their condition.”
According to the National Institutes of Health, estimated 42 million people are affected by constipation. Chronic idiopathic constipation is a diagnosis given to those who experience constipation continuously and for which there is no structural or biochemical explanation.
Radius is taken daily in oral form, encouraging secretion of intestinal fluid and working at the local level in the upper GI path to support the regular intestinal function.
The safety and efficacy of the trilulence was established in two weeks, a playbo-controlled trial involving 1,775 adult participants. Participants were randomly assigned to receive a placebo or treulen, once for those who participated in daily trials, there was to be a constriction in the first six months before the study began and three in three months in the last three months Apart from being less bacteria, there were also other symptoms associated with constipation. The participants receiving trilens were more likely to experience improvement in the frequency of complete natural bowel movement compared to those who received Plastbob, and improved stool frequency and stability and stress.
Trulance should not be used in children under the age of six due to the risk of serious dehydration. Disease should be prevented from patients aged 6 years and 18 years old. The security and effectiveness of the trulance has not been established in patients under the age of 18. Trulance should not be used in known or suspected mechanical gastrointestinal blocking patients.
The most common and serious side effects of trilulence were diarrhea. Patients may experience severe diarrhea if severe diarrhea occurs, patients should stop taking trumpets and contact their health care provider.
Trulance is manufactured by New York, New York based Synergy Pharmaceuticals Inc.
U.S. An agency within the Department of Health and Human Services, the FDA protects public health by assuring the safety, effectiveness and safety of human, veterinary drugs, vaccines and other biological products, and medical devices for human use. This agency is responsible for the safety and security of our country’s food supply, cosmetics, food supplements, electronic radiation products, and regulation of tobacco products.